A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Stopped Unable to enroll due to criteria for stable baseline pain
Conditions
- Castrate-Resistant Prostate Cancer
- Hormone Refractory Prostate Cancer
Interventions
- DRUG: custirsen sodium
- DRUG: isotonic, 0.9% sodium chloride
- DRUG: docetaxel
- DRUG: cabazitaxel
- DRUG: prednisone
Sponsor
Achieve Life Sciences
Collaborators